Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Bortezomib”

936 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 936 results

Testing effectiveness (Phase 2)Study completedNCT02703779
What this trial is testing

Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Siddhartha Ganguly 101
Early research (Phase 1)Study completedNCT00382954
What this trial is testing

Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML

Who this might be right for
Acute Myelogenous Leukemia
University of Kentucky 55
Testing effectiveness (Phase 2)Ended earlyNCT01783522
What this trial is testing

Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib

Who this might be right for
Chemotherapeutic Agent ToxicityMultiple MyelomaPeripheral Neuropathy
Beth Faiman 9
Testing effectiveness (Phase 2)Study completedNCT00967369
What this trial is testing

Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

Who this might be right for
Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
M.D. Anderson Cancer Center 20
Testing effectiveness (Phase 2)WithdrawnNCT00706953
What this trial is testing

Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

Who this might be right for
Multiple Myeloma
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Not applicableNo Longer AvailableNCT00063791
What this trial is testing

Assess Two Different Strategies of Combining Dexamethasone and VELCADE

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Study completedNCT01873157
What this trial is testing

Bortezomib in Late Antibody-mediated Kidney Transplant Rejection

Who this might be right for
Late Rejection of Renal TransplantAntibody-mediated Rejection
Medical University of Vienna 44
Testing effectiveness (Phase 2)Study completedNCT01668719
What this trial is testing

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

Who this might be right for
DS Stage I Plasma Cell MyelomaDS Stage II Plasma Cell MyelomaDS Stage III Plasma Cell Myeloma
SWOG Cancer Research Network 142
Testing effectiveness (Phase 2)Ended earlyNCT00283634
What this trial is testing

Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

Who this might be right for
NSCLC
Millennium Pharmaceuticals, Inc.
Testing effectiveness (Phase 2)Ended earlyNCT00985907
What this trial is testing

Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaPatient Participation
University of California, San Francisco 13
Testing effectiveness (Phase 2)Study completedNCT00708292
What this trial is testing

A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Novartis Pharmaceuticals 29
Testing effectiveness (Phase 2)WithdrawnNCT06348147
What this trial is testing

Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

Who this might be right for
Newly Diagnosed Multiple MyelomaMultiple MyelomaAutologous Stem Cell Transplantation
UNC Lineberger Comprehensive Cancer Center
Large-scale testing (Phase 3)Study completedNCT01916252
What this trial is testing

Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old

Who this might be right for
Multiple Myeloma
PETHEMA Foundation 460
Testing effectiveness (Phase 2)Study completedNCT00084747
What this trial is testing

Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Jonsson Comprehensive Cancer Center 30
Testing effectiveness (Phase 2)Study completedNCT01168804
What this trial is testing

Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Austrian Forum Against Cancer 79
Testing effectiveness (Phase 2)Ended earlyNCT00923247
What this trial is testing

A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

Who this might be right for
Medullary Thyroid Carcinoma
National Cancer Institute (NCI) 22
Testing effectiveness (Phase 2)Active Not RecruitingNCT05392946
What this trial is testing

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Who this might be right for
Plasma Cell Myeloma
Mayo Clinic 49
Large-scale testing (Phase 3)Not Yet RecruitingNCT07665450
What this trial is testing

Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 1,000
Testing effectiveness (Phase 2)Study completedNCT02308280
What this trial is testing

Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients

Who this might be right for
Multiple MyelomaHigh-Risk Cancer
Maisonneuve-Rosemont Hospital 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT04166565
What this trial is testing

Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease

Who this might be right for
Multiple MyelomaExtramedullary Plasmacytoma
Stichting European Myeloma Network 41
Next Page